Vinay Prasad Reinstated as FDA Biologics Director

Vinay Prasad, recently ousted after only a few months as head of the FDA's Center for Biologics Evaluation and Research, will return to his leadership role, according to the Department of Health and Human Services. Prasad departed on July 30 amid criticism from right-wing figures, including Laura Loomer, and controversy over a pause in Sarepta Therapeutics’ gene therapy shipments for Duchenne muscular dystrophy due to safety concerns. The FDA has since reversed its decision, allowing Sarepta shipments to resume. HHS emphasized that neither the White House nor the department would let media distractions affect the FDA's work under the Trump administration. Prasad's return occurs as Health Secretary Robert F. Kennedy Jr. oversees broader shake-ups at the FDA and other health agencies. It remains uncertain if Prasad will retain all of his previous titles within the agency.